drugset / Trial / NCT00196625

Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-infected Patients in Virological Failure.

NCT00196625

Phase 2 Completed 100 enrolled ANRS, Emerging Infectious Diseases
RandomizedParallel-groupOpen-labelTreatment

Summary

HIV infected patients are treated with highly active antiretroviral therapy (HAART). Side effects and the great number of pills reduces adherence to the treatment, and induces therapeutic failure. In order to maintain efficacy of HAART, new combination is evaluated. The aim of the study is to compare the antiviral efficacy of this salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors, over a 26-week period in HIV-infected patients in whom multiple antiretroviral regimens had failed.

Timeline

Start
2000-11
Primary completion
Completion
2002-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Amprenavir Other / unclassified 600 mg
Subject Lopinavir Other / unclassified 400 mg
Subject Ritonavir Other / unclassified 100 mg
Subject Ritonavir Other / unclassified 200 mg